Eli Lillys Breakthroughs Hedge Funds New Healthcare Favorite
| PHPIX Fund | USD 27.85 0.48 1.75% |
Slightly above 54% of Pharmaceuticals Ultrasector's investors are presently thinking to get in. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that some investors are interested at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company stands against other most promising healthcare stocks according to hedge funds. The Healthcare Sector Growth, Innovation, and the Impact of AI The healthcare
Read at finance.yahoo.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in price to earning among similar funds. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| LGPSX | Profunds Large | 0.87 | ||||
| LGPIX | Large Cap | 0.85 | ||||
| UIPSX | Ultrashort Mid-cap | 0.71 | ||||
| UIPIX | Ultrashort Mid-cap | 0.69 | ||||
| BRPIX | Bear Profund | 0.44 | ||||
| BRPSX | Bear Profund | 0.39 | ||||
| SRPSX | Short Real | 0.61 | ||||
| SRPIX | Short Real | 0.65 | ||||
| TEPIX | Technology Ultrasector | 2.08 | ||||
| TEPSX | Technology Ultrasector | 2.08 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |